Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the Functional Assessment of Cancer Therapy-Lung scale

Seminars in Oncology

Volumn 30, Issue 1 SUPPL. 1, 2003, Pages 39-48

  Cella, David ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEFITINIB; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACNE; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RASH; RECURRENT CANCER; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0037295432     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50031     Document Type: Review

References (25)

1. Earle CC, Evans WK: Management issues for stage IV non-small-cell lung cancer. Cancer Control 4:307-316, 1997
2. Hollen PJ, Gralla RJ, Kris MG, et al: Quality of life assessment in individuals with lung cancer. Testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 29A:S51-S58, 1993 (suppl 1)
3. Soni MK, Cella DF, Masters GA, et al: The validity and clinical utility of symptom monitoring in advanced lung cancer: A literature review. Clin Lung Cancer 4:1-8, 2002
4. Jacobsen PB, Weltzer MA: Evaluation of palliative endpoints in oncology clinical trials. Cancer Control 6:471-477, 1999
5. Cella DF, Bonomi AE, Lloyd SR, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199-220, 1995
6. Sarna L: Fluctuations in physical function: Adults with non-small cell lung cancer. J Adv Nurs 18:714-724, 1993
7. Sarna L: Functional status in women with lung cancer. Cancer Nurs 17:87-93, 1994
8. Montazeri A, Milroy R, Hole D, et al: Quality of life in lung cancer patients: An important prognostic factor. Lung Cancer 31:233-240, 2001
9. Langendijk H, Aaronson NK, de Jong JMA, et al: The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 55:19-25, 2000
10. Cella D, Webster K: Linking outcomes management to quality-of-life measurement. Oncology (Huntingt) 11:232-235, 1997
11. Rowinsky EK: EGFR-targeted cancer therapies: Is there a need to reconsider clinical trial design? A discussion of how, and why, clinical trial design should be altered for the clinical evaluation of EGRF-targeted cancer therapies. Signal 2:4-12, 2001
12. Barsevick A, Langer C, Brunet D, et al: Correlation of quality of life (QOL) with survival, treatment response, and anemia in patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel. Proc Am Soc Clin Oncol 16:44a, 1997 (abstr 153)
13. Jagasia M, Johnson DH, Hande KR, et al: Quality of life (QOL) predicts response to therapy and improve during the treatment of non-small cell lung cancer (NSCLC) patients with paclitaxel (P) and carboplatin (C). Proc Am Soc Clin Oncol 17:466, 1998 (abstr)
14. Cella D, Eton DT, Fairclough DL, et al: What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 55:285-295, 2002
15. Cella DF, Eton DT, Fairclough DL, et al: What is a clinically meaningful change (CMC) on the Functional Assessment of Cancer Therapy-Lung (FACT-L): Analysis of ECOG 5592 data. Proc Am Soc Clin Oncol 20:345a, 2001 (abstr 1376)
16. Cella D, Eton DT, Fairclough DL, et al: What is a clinically meaningful change (CMC) on the Functional Assessment of Cancer Therapy-Lung (FACT-L): Analysis of ECOG 5592 data. Presented at the Thirty-Seventh Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001
17. Ferry D, Hammond L, Ranson M, et al: Intermittent oral Zd1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase, inhibitor (Egfr-Tki) shows evidence of good tolerability and activity: Final results from a phase I study. Proc Am Soc Clin Oncol 19:3a, 2000 (abstr 5E)
18. Fukuoka M, Yano S, Giaccone, G, et al: Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 21:298a, 2002 (abstr 1188)
19. Douillard J-Y, Giaccone G, Horai T, et al: Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1). Proc Am Soc Clin Oncol 21: 299a, 2002 (abstr 1195)
20. Kris MG, Natale RB, Herbst RS, et al: A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxelbased regimens (IDEAL 2). Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1166)
21. Natale RB, Skarin AT, Maddox A-M, et al: Improvement in symptoms and quality of life for advanced non-smallcell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1167)
22. Douillard J-Y, Giaccone G, Horai T, et al: Non-smallcell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (Ideal 1). Presented at the Thirty-Eighth Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002
23. Natale R, Skarin A, Maddox A, et al: Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Presented at the Thirty-Eighth Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002
24. Kris M: A phase II trial of ZD1839 ('Iressa') in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regiment (Ideal 2). Presented at the Thirty-Eighth Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002
25. Fukuoka M: Final results from a phase II trial of ZD1839 ('Iressa') for patients with previously treated advanced non-small-cell lung cancer (Ideal 1). Presented at the Thirty-Eighth Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002